跳至主要内容
临床试验/NCT07617025
NCT07617025招募中不适用

Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer

Angela Toss6 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
6

研究概览

简要总结

This study is an observational study being carried out in several hospitals. No extra tests or procedures are required beyond those already part of normal medical care.

The study is sponsored by the University of Modena and Reggio Emilia and aims to include about 100 patients.

The main goal of the study is to better understand the different biological types of breast cancer in patients who have hormone receptor-positive (HR-positive), HER2-negative breast cancer related to BRCA gene mutations. In particular, the study will explore whether these cancers tend to belong to molecular types that may respond less to endocrine or CDK4/6 inhibitor therapy.

The study also compares cancers linked to BRCA1 and BRCA2 mutations and investigates whether the different biological types are associated with differences in disease outcomes and response to treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years or older
  • Patients carrying a pathogenic or likely pathogenic germline variant in BRCA1 or BRCA2 with a histologically confirmed diagnosis of HR+/HER2-negative breast cancer
  • Patients with available hospital and/or outpatient medical records for clinical data collection
  • Presence of available formally fixed paraffin-embedded (FFPE) breast tumor tissue (primary or metastatic site)

排除标准

  • 未提供

研究者

发起方
Angela Toss
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Angela Toss

Prof

University of Modena and Reggio Emilia

研究点 (6)

Loading locations...

相似试验